1162656-22-5
MCB-613
CAS: 1162656-22-5
Molecular Formula: C20H20N2O
1162656-22-5 - Names and Identifiers
1162656-22-5 - Physico-chemical Properties
| Molecular Formula | C20H20N2O |
| Molar Mass | 304.39 |
| Density | 1.159±0.06 g/cm3(Predicted) |
| Boling Point | 510.4±50.0 °C(Predicted) |
| Solubility | DMSO: 10 mg/mL |
| pKa | 4.36±0.12(Predicted) |
| Storage Condition | Sealed in dry,Room Temperature |
1162656-22-5 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.285 ml | 16.427 ml | 32.853 ml |
| 5 mM | 0.657 ml | 3.285 ml | 6.571 ml |
| 10 mM | 0.329 ml | 1.643 ml | 3.285 ml |
| 5 mM | 0.066 ml | 0.329 ml | 0.657 ml |
Last Update：2024-01-02 23:10:35
1162656-22-5 - Reference Information
| preparation | with 3-pyridinecarboxaldehyde and p-ethylcyclohexanone as raw materials, bipyridine α was obtained by Claisen-Schmidt condensation reaction, Β-unsaturated ketone intermediate 4-ethyl-2, 6-bis (pyridine-3-methylene) cyclohexanone. Dry HCl was used as the catalyst for the condensation reaction. The operation was simple and the yield was over 85%. |
| biological activity | MCB-613 is a potent steroid receptor coactivator (SRC) small molecule "stimulators" (SMS), super-stimulate the transcriptional activity of SRCs. MCB-613 increases the interaction of SRC with other co-activators and significantly induces ER stress in combination with the production of reactive oxygen species (ROS). MCB-613 is an SMS that targets oncogenes as anticancer drugs by overstimulating the SRC oncogenic program. |
| Cell Line: | MDA-MB-231 cells HeLa cells SRC-3 KO and WT HeLa cells |
| Concentration: | 6 μM; 8 μM 2 μM; 4 μM; 6 μM; 8 μM; 10 μM 3 μM; 4 μM; 5 μM; 6 μM; 7 μM |
| Incubation Time: | 24 hours 24 hours 24 hours |
| Result: | Increased MMP13 mRNA expression. Induced the p-eIF2α, p-IRE1α, and ATF-4 protein expression. Decreased SRC-3 KO and WT HeLa cell viability. Inhibited tumor growth in vivo. |
| Animal Model: | MCF-7 breast cancer mouse xenograft model (athymic nude mice by injecting MCF-7 cells into mammary fat pads) |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection; 20 mg/kg; 3 times/week; 7 weeks |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
Product Name: MCB-613 Visit Supplier Webpage Request for quotation
CAS: 1162656-22-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
CAS: 1162656-22-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Spot supply
Product Name: MCB-613 Visit Supplier Webpage Request for quotationCAS: 1162656-22-5
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
Product Name: MCB-613 Visit Supplier Webpage Request for quotation
CAS: 1162656-22-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
CAS: 1162656-22-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
View History
1162656-22-5
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-N-cyclohexyl-N-((cyclohexyla mino)carbonyl)-1,3-dimethyl-2,6-dioxo-
4,4'-[(1R,3R)-cyclohexane-1,3-diyldi(E)-ethene-2,1-diyl]dibenzonitrile
7-BroMo-2-Methyl-1-propyl-1,3-benzodiazole-5-carboxylic acid
6-BroMo-2-oxo-2,3,4,8-tetrahydro-1,8-naphthyridine-3-carboxylic acid
2-(butylsulfanyl)-3-(4-methoxyphenyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
(S)-(-)-Propylene oxide
10417-63-7
isobutyraldehyde oxime
2370013-39-9
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-N-cyclohexyl-N-((cyclohexyla mino)carbonyl)-1,3-dimethyl-2,6-dioxo-
4,4'-[(1R,3R)-cyclohexane-1,3-diyldi(E)-ethene-2,1-diyl]dibenzonitrile
7-BroMo-2-Methyl-1-propyl-1,3-benzodiazole-5-carboxylic acid
6-BroMo-2-oxo-2,3,4,8-tetrahydro-1,8-naphthyridine-3-carboxylic acid
2-(butylsulfanyl)-3-(4-methoxyphenyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
(S)-(-)-Propylene oxide
10417-63-7
isobutyraldehyde oxime
2370013-39-9